A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Status:
Active, not recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.

Phase 4

Memorial Sloan Kettering Cancer Center

Angiopeptin
Lanreotide
Octreotide
Somatostatin